Core Viewpoint - PMGC Holdings Inc.'s subsidiary, NorthStrive Biosciences, has announced a third amendment to its License Agreement with MOA Life Plus Co., Ltd. to update the development timeline and milestones for its clinical programs EL-32 and EL-22 [1][2]. Company Overview - PMGC Holdings Inc. is a diversified holding company that focuses on managing and growing its portfolio through strategic acquisitions and investments across various industries [5]. - NorthStrive Biosciences Inc. is a biopharmaceutical company under PMGC, concentrating on the development of innovative aesthetic medicines, with its lead asset EL-22 targeting obesity treatment while preserving muscle during weight loss [4]. Partnership Details - The amendment to the License Agreement aligns the development schedule of EL-32 and EL-22 with the research and regulatory expectations of both parties, reinforcing NorthStrive's commitment to disciplined development planning [2]. - MOA Life Plus Co. Ltd. is a Korean biotechnology firm dedicated to the research and commercialization of therapeutic and wellness technologies, partnering globally to enhance scientific innovation in health applications [3].